이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dyne Therapeutics 관리

관리 기준 확인 2/4

Dyne Therapeutics' CEO는 John Cox, Mar2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 331.36K 가치에 해당하는 회사 주식의 0.01% 직접 소유합니다. 331.36K. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 4.6 년입니다.

주요 정보

John Cox

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.01%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

Jan 11

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Jan 08

CEO

John Cox (61 yo)

less than a year

테뉴어

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He serves as Chairman of the Board at Minovia Therapeutics LTD. He joined Minov...

리더십 팀

이름	위치	테뉴어	보상	소유권
Susanna High	Chief Operating Officer	3.9yrs	US$2.04m	0.014% $ 480.2k
Jonathan McNeill	Chief Business Officer	2.9yrs	US$2.23m	0.012% $ 404.5k
John Cox	CEO, President & Director	less than a year	데이터 없음	0.010% $ 339.0k
Romesh Subramanian	Co-Founder & Advisor	no data	US$4.37m	데이터 없음
Richard Scalzo	Senior VP and Head of Finance & Administration	3.9yrs	데이터 없음	0.0068% $ 228.7k
John Najim	Chief Technical Officer	1.2yrs	데이터 없음	데이터 없음
Oxana Beskrovnaya	Chief Scientific Officer	3yrs	US$1.49m	0.022% $ 745.5k
Amy Reilly	Senior VP and Head of Corporate Communications & Investor Relations	3.9yrs	데이터 없음	데이터 없음
Daniel Wilson	Senior VP & Head of Legal	4yrs	데이터 없음	데이터 없음
Kate Mitchell	VP & Head of Human Resources	1.9yrs	데이터 없음	데이터 없음
Debra Feldman	Chief Regulatory Affairs Officer	4.1yrs	데이터 없음	데이터 없음
Ashish Dugar	Chief Medical Affairs Officer	3.3yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: DYN 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Cox	CEO, President & Director	less than a year	데이터 없음	0.010% $ 339.0k
Sudhir Agrawal	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Edward Hurwitz	Independent Director	5.6yrs	US$250.17k	0% $ 0
David Lubner	Independent Director	4.3yrs	US$264.17k	0.054% $ 1.8m
Jason Rhodes	Independent Chairman	6.5yrs	US$283.17k	0% $ 0
Dirk Kersten	Independent Director	5.6yrs	US$262.67k	0% $ 0
Francesco Muntoni	Member of Scientific Advisory Board	3.9yrs	데이터 없음	데이터 없음
Louis Kunkel	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Nancy Andrews	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Catherine Stehman-Breen	Independent Director	5yrs	US$253.92k	0.090% $ 3.0m
Charles Thornton	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Statland	Member of Scientific Advisory Board	4.1yrs	데이터 없음	데이터 없음

4.6yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: DYN 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

Dyne Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Recent updates

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics, Inc. Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Dyne Therapeutics Presents New Preclinical Data from Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10